Hypochondroplasia

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

7 events
Apr 2026Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

QED Therapeutics, a BridgeBio company — PHASE2

TrialENROLLING BY INVITATION
Jul 2025A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

BioMarin Pharmaceutical — PHASE2

TrialRECRUITING
Jun 2025Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

BioMarin Pharmaceutical — PHASE3

TrialENROLLING BY INVITATION
Apr 2025An Interventional Study of Infigratinib in Children With Hypochondroplasia

QED Therapeutics, a BridgeBio company — PHASE2, PHASE3

TrialENROLLING BY INVITATION
Jun 2024Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

BioMarin Pharmaceutical — PHASE3

TrialACTIVE NOT RECRUITING
Jun 2024Prospective Clinical Assessment Study in Children With Hypochondroplasia

QED Therapeutics, a BridgeBio company

TrialRECRUITING
Nov 2023A Multicenter Multinational Observational Study of Children With Hypochondroplasia

BioMarin Pharmaceutical

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Hypochondroplasia.
Check the disease page for updates →

Clinical Trial Landscape

7 active trials
2Phase 3
2Phase 2
2Unknown
1PHASE2, PHASE3
7Total recruiting
Search clinical trials for Hypochondroplasia

Recent News & Research

No recent news articles indexed yet for Hypochondroplasia.
Search PubMed for Hypochondroplasia

Browse all Hypochondroplasia news →

Specialist Network

Top 4 by expertise

View all Hypochondroplasia specialists →

Quick Actions